MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

$FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma$

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

24 Jul 2024

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally...

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

Organon to Present New Analysis of VTAMA® (tapinarof) Cream, 1%

Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

By Bruker Corporation
Bruker Corporation
10 Aug 2026

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

By Avantik
Avantik
10 Aug 2026

BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

By BioVigil
BioVigil
10 Aug 2026

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

By Merck & Co., Inc
Merck & Co., Inc
06 Aug 2026

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

By Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
05 Aug 2026

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

By SHARx
SHARx
04 Aug 2026

Most Popular

IMFINZI plus neoadjuvant EV improved survival outcomes in muscle-invasive bladder cancer in the Phase III VOLGA trial

By AstraZeneca

May 14
"Latigo Biotherapeutics has been granted FDA Fast Track Designation for LTG-001, a potential best-in-class Nav1.8 inhibitor for the non-opioid treatment of acute pain

By Latigo Biotherapeutics

Mar 03
HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

By HanchorBio Inc.

Nov 10

August 2026

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Search your requirement

Social media

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

Organon to Present New Analysis of VTAMA® (tapinarof) Cream, 1%

Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Most Popular

IMFINZI plus neoadjuvant EV improved survival outcomes in muscle-invasive bladder cancer in the Phase III VOLGA trial

"Latigo Biotherapeutics has been granted FDA Fast Track Designation for LTG-001, a potential best-in-class Nav1.8 inhibitor for the non-opioid treatment of acute pain

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

User Area

Discover

Engage with Us

Search your requirement

Social media

Featured Press Releases

Most Popular

User Area

Discover

Engage with Us

Subscribe to Our Monthly Newsletter